Why this fund manager is 'very happy' to own this ASX 200 share

The ASX 200 stock has come under some selling pressure in 2023, but this fundie sees better days ahead.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

S&P/ASX 200 Index share CSL Ltd (ASX: CSL) is historically a long-term outperformer. But the stock has struggled in 2023.

Shares in the biotechnology company are currently trading for $266.80 apiece, down 5.3% since the opening bell of 3 January. That compares to a 3% gain posted by the ASX 200.

Here's why the ASX 200 share has come under pressure. And why this fund manager is "very happy" to own the biotech company.

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.

Image source: Getty Images

What's happening with the ASX 200 share?

As you can see in the chart above, the CSL share price really hit some turbulence on 14 June.

That came after the ASX 200 share announced a downgrade of its FY 2023 profit guidance. This was driven by higher than initially forecast foreign currency headwinds.

At the time, CSL revised its forecast for its full-year net profits after tax and amortisation (NPATA) to the range of US$2.9 billion to US$3 billion in constant currency.

That revision saw the ASX 200 share close the day down 6.9%.

CSL reported its audited results on 15 August. And NPATA came in right near the bottom end of that forecast, at US$2.86 billion.

Other highlights of the FY 2023 results included a 31% increase in revenue in constant currency to US$13.31 billion. And the full-year dividend increased 6% to US$2.36 per share.

Management also reaffirmed its FY 2024 guidance. They expect NPATA of in the range of US$2.9 billion to US$3 billion in constant currency. And FY 2024 revenue growth of 9% to 11%.

Which brings us to Patrick Hodgens, managing director Firetrail Investments.

CSL counts amongst the biggest holdings at Firetrail Investments' high conviction fund.

And Hodgens wasn't put off by the ASX 200 share's results.

According to The Australian Financial Review, Firetrail believes this is a case of CEO Paul McKenzie "looking to reset".

According to Hodgens:

We're very happy to be owning CSL over the medium term and, in fact, we bought quite a bit more on the back of that perceived weakness by the market. We think CSL has some really good earnings upside if you look out two to three years.

CSL share price snapshot

As mentioned above, the CSL share price has underperformed in 2023 and over the past 12 months.

The ASX 200 share has outperformed longer-term, up 27% in five years.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Female scientist working in a laboratory.
Healthcare Shares

This ASX biotech stock could more than double Canaccord Genuity says

This company has more than one iron in the fire.

Read more »

A medical researcher wearing a white coat sits at her desk in a laboratory conducting a test.
Healthcare Shares

This ASX biotech's shares just hit a new 12-month high, up more than 700% over a year. Here's why

Good news has this company's shares on the up.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Share Market News

Up 68% from a multi-year low. Are Telix shares a buy, sell or hold?

Telix shares crashed to just $8.63 per share in mid-February.

Read more »

Health professional working on his laptop.
Broker Notes

Are Orthocell shares a buy after crashing 7% yesterday?

These healthcare shares could be on discount right now.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

2 ASX healthcare shares I think can beat the market

Healthcare trends like ageing populations and rising demand can create long-term opportunities.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Up 2,000% in a year, why this ASX healthcare stock is in focus today

4DMedical shares rise as multiple updates land across key markets.

Read more »

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Orthocell caps 26% surge this week with first US Military Surgery

The company's commercial rollout is off to a good start.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

This ASX health tech stock just hit a new record high. Could it go even higher?

Morgans believes there's still upside to be had.

Read more »